

Rapid Distinction and Semiquantitative Analysis of THC and CBD by Silver-Impregnated Paper Spray Mass Spectrometry

Si Huang, Frank W. Claassen, Teris A. van Beek, Bo Chen, Jianguo Zeng, Han Zuilhof,* and Gert IJ. Salentijn*

Cite This: *Anal. Chem.* 2021, 93, 3794–3802

Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: The control over the amount of psychoactive THC (Δ -9-tetrahydrocannabinol) in commercial cannabidiol (CBD) products has to be strict. A fast and simple semiquantitative Ag(I)-impregnated paper spray mass spectrometric method for differentiating between THC and CBD, which show no difference in standard single-stage or tandem MS, was established. Because of a different binding affinity to Ag(I) ions, quasi-molecular Ag(I) adducts $[\text{THC} + \text{Ag}]^+$ and $[\text{CBD} + \text{Ag}]^+$ at m/z 421 and 423 give different fragmentation patterns. The product ions at m/z 313 for THC and m/z 353 and 355 for CBD can be used to distinguish THC and CBD and to determine their ratio. Quantification of THC/CBD ratios in commercial CBD oils was accomplished with a low matrix effect ($-2.2 \pm 0.4\%$ for THC and $-2.0 \pm 0.3\%$ for CBD). After simple methanol extraction (recovery of $87.3 \pm 1.2\%$ for THC and $92.3 \pm 1.4\%$ for CBD), Ag(I)-impregnated paper spray analysis was employed to determine this ratio. A single run can be completed in a few minutes. This method was benchmarked against the UHPLC-UV method. Ag(I)-impregnated paper spray MS had the same working range (THC/CBD = 0.001–1) as UHPLC-UV analysis ($R^2 = 0.9896$ and $R^2 = 0.9998$, respectively), as well as comparable accuracy (-2.7 to 14%) and precision (RSD 1.7–11%). The method was further validated by the analysis of 10 commercial oils by Ag(I)-impregnated paper spray MS and UHPLC-UV analysis. Based on the determined relative concentration ratios of THC/CBD and the declared CBD concentration, 6 out of 10 CBD oils appear to contain more THC than the Dutch legal limit of 0.05%.



Cannabis (*Cannabis sativa* L.) has been cultivated for medicinal, recreational, and industrial purposes since ancient times and remains a widely cultivated plant.¹ Among its identified cannabinoids, Δ -9-tetrahydrocannabinol (THC) and cannabidiol (CBD), and their carboxylated forms, Δ -9-tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), are the most sought after by people because of their psychoactive and therapeutic effects.² THC is responsible for the psychoactive effects and has some potential analgesic, antiemetic, antikinetic, and appetite-stimulating properties.³ CBD is not psychoactive but exhibits similar beneficial effects as THC.⁴

The absence of psychoactive effects and the abundance of anecdotal claims of the effectiveness of CBD across a wide variety of conditions in both mainstream and social media have created significant public interest in CBD products, typically as oils. Such interest has led to increased consumer availability. Generally, commercially available CBD oils mainly consist of CBD and carrier oil and may contain flavorings, terpenes, or other cannabinoids like CBDA or trace amounts of THCA and THC.⁵ Incorrect or misleading labels for the cannabinoid content of CBD products and indiscriminate use of CBD may lead to various issues. The presence of THC in commercial CBD oils can occur because of the fact that even CBD-rich varieties of cannabis produce a small amount of THC.⁶


Therefore, naturally derived CBD extracts may contain some THC in the final products, and oil consumers could thus be taking THC without knowing so. Additionally, if the THC content of a CBD product exceeds the maximally allowed limit, this could lead to legal problems. Many nations stipulate a zero-tolerance policy or a maximum THC level (0.05–1%) for CBD products.^{6,7}

As THC and CBD are structural isomers (accurate molecular weight of 314.2246 Da), differentiating as well as quantifying THC and CBD is challenging. Generally, gas chromatography (GC)- or liquid chromatography (LC)-based techniques are employed, and typically run times of 10–20 min are required to achieve baseline separation.⁸ Additionally, for GC-based techniques, the detection of the acidic precursors THCA and CBDA (accurate molecular weight of 358.2144 Da) is not feasible without derivatization.⁹

Received: October 10, 2020

Accepted: February 2, 2021

Published: February 12, 2021



Simple and rapid methods to screen THC and CBD have been developed, including electrochemical² and colorimetric^{10,11} approaches. However, these methods cannot differentiate cannabinolic acids (THCA and CBDA) from the respective cannabinol forms (THC and CBD)² or distinguish THC and CBD;¹¹ moreover, these methods cannot achieve quantitative results.¹⁰

Even with mass spectrometry (MS), it is difficult to differentiate between THC and CBD as they have the same mass and give identical collision-induced dissociation (CID) fragmentation patterns in positive ionization mode.¹² In negative mode, it has been reported that there may exist a unique THC MS/MS fragment (m/z 191) under specific conditions, which could allow the differentiation of these two compounds to some extent.¹³ However, in another report, this fragment—under different conditions—has also been demonstrated for CBD.¹⁴ Therefore, only relying on this fragment for distinguishing between the isomers and their quantification remains challenging.

To enhance MS performance and improve ionization efficiency, adduct formation with Ag(I) ions has been exploited in ion mobility spectrometry,¹⁵ electrospray ionization mass spectrometry (ESI-MS),^{16–18} secondary ion mass spectrometry,¹⁹ and matrix-assisted laser desorption ionization mass spectrometry.²⁰ Ag(I) coordinates strongly with alkenes and weakly with polar groups like hydroxyls. The presence of multiple isolated C=C bonds, especially 1,5-dienes, strongly increases complexation, which is used in the analysis of certain olefinic compounds.^{21–23} However, to the best of our knowledge, Ag(I) adduct formation has been rarely applied to ambient ionization mass spectrometry (AIMS),²⁴ with the notable exception of improving the detection of olefins with desorption electrospray ionization (DESI)-MS.²⁵

Paper spray ionization mass spectrometry (PS-MS), first reported in 2010,²⁶ is an AIMS method, well known for its fast analysis at low cost of consumables.²⁷ In PS-MS, analytes are ionized from a paper tip by application of a solvent and an electric field, and thus it is one of the many variants of electrospray ionization.²⁸ Importantly, paper can be readily modified to enhance PS-MS selectivity and sensitivity through surface modification or coating.^{27–30}

In this work, we investigated the combination of Ag(I) ions and PS-MS for the rapid and selective analysis of THC and CBD, in particular for detecting low concentrations of THC in CBD oils. Based on the different complexations of THC (weak; single alkene C=C bond) and CBD (strong; 1,5-diene moiety) with Ag(I) ions,²¹ we hypothesized that the formed THC and CBD Ag(I) adducts will exhibit different stabilities. In turn, this could lead to different fragmentation patterns in tandem MS. If so, simple and fast differentiation of THC and CBD as well as semiquantitative analysis should be achievable. As hypothesized, the quasi-molecular Ag(I) adducts of THC [THC + Ag]⁺ and CBD [CBD + Ag]⁺ at m/z 421 and 423 give different product ions in tandem MS, at m/z 313 for THC and m/z 353 and 355 for CBD. These product ions were then used to distinguish between THC and CBD and to determine their ratio within a few minutes in commercial CBD oils.

MATERIALS AND METHODS

Chemicals and Reagents. Acetonitrile, methanol, and *tert*-butyl methyl ether (MTBE; HPLC-grade) were purchased from Biosolve Chimie SARL (Dieuze, France). Formic acid (HPLC-grade) and silver nitrate (analytical grade) were

purchased from Fisher Scientific (Loughborough, Leicestershire). Deionized water was obtained from a Milli-Q Direct ultrapure water system (Millipore, USA). THC and CBD standards were obtained from cannabis flowers and CBD oil, respectively. According to nuclear magnetic resonance (NMR), thin layer chromatography (TLC), and UHPLC-UV data (Supporting Information, Figures S1–S3), their purity was >98%. Chromatography paper was purchased from Hangzhou Special Paper Co., Ltd. (Hangzhou, China). Different brands of pure CBD oils were purchased from health shops (Wageningen, the Netherlands) or ordered online. Information on all CBD oils is shown in the Supporting Information, Table S1. Ammonium acetate (analytical grade) was obtained from Merck (Darmstadt, Germany). Santonin (analytical grade) was purchased from Sigma (St. Louis, MO, USA).

Preparation of Paper Substrate. Chromatography paper was cut into isosceles triangles with a height of 10 mm and a base of 5 mm, employing a paper cutter made in-house. These paper tips were put in a bottle with methanol and washed for 30 min in an ultrasonic bath at room temperature. Afterward, methanol was decanted, and the bottle with tips was placed in a fume hood for 30 min at room temperature and then dried at 60 °C in a vacuum oven for 12 h. The resulting paper tips are referred to as *clean*.

Preparation of Ag(I)-Impregnated Paper Substrate. For the preparation of Ag(I)-impregnated tips, 60 mL of ultrapure water was added to 1.02 g silver nitrate in a 125 mL wide-mouth brown bottle, which was placed in an ultrasonic bath for 2 min to obtain a 0.10 mol L^{−1} AgNO₃ solution. *Clean* paper tips were immersed in the AgNO₃ solution, and after capping, the bottle was placed in an ultrasonic bath. After 15 min of sonication, water in the ultrasound bath was replaced because otherwise the temperature of water would become too high (should not be above ca. 40 °C), making the surface of the paper rough or even damaging the tips. After another 15 min, the AgNO₃ solution was decanted, and the bottle without cap was heated in an oven at 100 °C for at least 1 h to evaporate most water. Finally, the tips were taken out of the bottle and dried in a vacuum oven at 60 °C for 12 h. Ag(I)-impregnated paper was put in tin foil and stored in a desiccator away from light. *Clean* paper tips were used for PS-MS, and the Ag(I)-impregnated paper tips were used for Ag(I)-impregnated paper spray MS (AgPS-MS).

Paper Spray Setup. The paper tip was positioned by an alligator clip, which was part of a modified DESI ion source (Prosolia, USA) equipped with a rotational and x – y – z positioner, and was directly connected to the HV supply of the ion source. The front of the paper tip was pointing toward the MS inlet at 4–6 mm. A sample solution of 15 μ L was added using an Eppendorf pipette (10–100 μ L). After this, a voltage of 4 kV was applied. The paper spray ion source was connected to either a high-resolution MS or to a linear ion trap MS.

Linear Ion Trap Mass Spectrometer. A Thermo LXQ linear ion trap mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) was used in positive mode, with a capillary voltage of 49 V, tube lens of 85 V, and a capillary temperature of 350 °C, unless indicated otherwise. All full-scan measurements were performed with a scan range of m/z 100.0–2000.0. For all MSⁿ fragmentation measurements, CID energy was determined as the energy at which the target product ions had the highest abundance while the precursor ion or ions had not

yet disappeared completely. The isolation width was set to include all desired target precursor ions.

Quadrupole Orbitrap High-Resolution Mass Spectrometer. For accurate mass measurements, the paper spray device was coupled to a Q-Exactive quadrupole orbitrap high-resolution MS (Thermo Fischer Scientific). All measurements were performed in positive mode with a mass resolution of 140,000 fwhm and a maximum injection time of 100 ms. The capillary temperature was 350 °C, and the S-lens RF level was 47. All full-scan measurements were performed with a scan range of m/z 100.0–2000.0. For molecular formula confirmation of the main peaks in MS¹ and MS² spectra, full-scan and CID fragmentation scan modes were used, respectively. For the determination of the molecular formula of the main peaks in MS³ and MS⁴ spectra from the LXQ analysis, in-source fragmentation and CID fragmentation were combined to provide higher energies for further fragmentation. Thermo Scientific Xcalibur 2.2 software was used for data acquisition and processing. The intensity of ions with m/z values within ± 5 ppm of the theoretical m/z is shown in the extracted ion chromatogram (EIC).

Ag(I) Complexation (Argentation) Chromatography–Mass Spectrometry. Following a previously described method,²¹ a strong cation exchange HPLC column (Nucleosil SA, 100 Å, 5 μ m, 2.1 \times 250 mm; Grace) was flushed with an aqueous 1% NH₄OAc solution at 0.50 mL min^{−1} for 1 h, followed by distilled water for 1 h. An aqueous AgNO₃ solution (0.20 g/mL) was injected onto the column *via* an autosampler in 50 μ L aliquots at 1 min intervals; 20 min after the last injection, the column was washed with MeOH for 1 h.

A 1220 Infinity II LC system (Agilent Technologies, Santa Clara, USA) was coupled to the LXQ MS. Separation of THC and CBD was achieved using the loaded Ag(I) column, with MeOH as the mobile phase, at a flow rate of 0.80 mL min^{−1}. The complexes of eluted compounds were directed into the LXQ MS and analyzed under full-scan or product ion scan mode. The LXQ settings were identical to those described for the PS-MS measurements except for the sheath gas flow rate of 15 (arbitrary units).

UHPLC-UV Analysis. A Zorbax Eclipse Plus C18 column (2.1 mm \times 50 mm, 1.8 μ m; Agilent Technologies, Santa Clara, CA, USA) was coupled to a 1290 Infinity ultra-high performance liquid chromatography (UHPLC) system (Agilent Technologies, Santa Clara, USA), with a diode array detector. The mobile phase consisted of 5 mM formic acid in both water (mobile phase A) and acetonitrile (mobile phase B), and the flow rate was 0.80 mL min^{−1}. Isocratic elution for 2 min with 25% B was followed by a gradient toward 100% B in 7 min. After being in this condition for 4 min, the system was returned to 25% B in 1 min and then re-equilibrated for 3 min at 25% B.³¹

Sample Preparation and Extraction. Stock solutions of THC and CBD were prepared in MeOH at 1.00 mg mL^{−1}. Samples for the determination of recovery, matrix effects, and calibration curves were constructed by spiking sunflower oil with THC or CBD stock solutions (see following sections). For extraction, 50.0 mg of spiked or blank oil was precisely weighed and 2.00 mL of MeOH was added. The extraction was performed by stirring samples with a magnetic stirring bar and a magnetic stirrer (IKA Labortechnik, IKAMAG RCT basic, Germany) for 1, 5, 10, 20, or 30 min. Afterward, 1.00 mL of the supernatant of each extracted sample was collected for analysis.

Commercial CBD oil samples were diluted with sunflower oil to 0.2% (w/w %) CBD in oil based on the labeled concentration. A magnetic stirring bar was used to stir the oil vigorously for 1 min. A 50.0 mg of the diluted CBD oil was precisely weighed for the following analysis. A 2.00 mL of MeOH was added to 50.0 mg of the diluted CBD oil for extraction. The extraction procedure was performed in triplicate by stirring these samples with a magnetic stirring bar for 1 min. A volume of 1.00 mL of the supernatant of each extracted sample was taken for further MS or UHPLC analysis.

Determination of Recovery and Matrix Effects. Extraction recovery and matrix effects were determined according to the procedure by Gottardo *et al.*,³² with minor modifications, as described below (see also [Supporting Information](#), Table S2).

Sunflower oil samples containing 0.20% THC (THC/oil, w/w %) and 0.20% CBD (CBD/oil, w/w %) were extracted with MeOH for 1, 5, 10, 20, and 30 min (sample type III, $n = 3$), whereas, for comparison, analogous extractions of the blank matrix (sunflower oil) were performed. These blank matrix extracts were then spiked with the same amount of THC and CBD per mL of methanol (sample type II, $n = 3$). The final methanolic solutions were analyzed by the UHPLC-UV method, and the recovery was calculated as the ratio of the averaged peak areas from set III to set II, expressed as a percentage (recovery (%) = III/II \times 100) for both THC and CBD.

For the matrix effect measurements, the same amounts of THC and CBD were spiked in the blank matrix extract (sample type II, $n = 3$) or pure MeOH (sample type I, $n = 3$). These methanolic solutions were analyzed by AgPS-MS. The EIC was normalized to the total ion chromatogram (TIC) to correct for the spray instability and irreproducibility (EIC/TIC). The matrix effect was calculated as the ratio of the THC MS² characteristic signal (m/z 313) from set II to set I, subtracted by 1, and expressed as a percentage (matrix effect (%) = (II/I − 1) \times 100). The matrix effect of CBD (m/z 353 + 355) was measured and calculated with the same methods as that for THC. A negative matrix effect percentage represents signal suppression and a positive percentage represents signal enhancement.

Calibration Curve Construction and Evaluation of Accuracy, Precision, LOD, and LOQ. THC and CBD stock solutions were used to prepare oil samples with different THC/CBD ratios (0.001, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, and 1; $n = 3$ per ratio), keeping the CBD content constant at 0.20% (CBD/oil, w/w %). To achieve this, appropriate volumes of methanolic stock solutions were mixed and dried under nitrogen and then reconstituted in 50.0 mg sunflower oil. These samples were extracted as described above, and the methanolic extract was analyzed with UHPLC-UV and AgPS-MS methods. The peak area ratios of THC/CBD at 215 nm or the characteristic MS² EIC area ratios of THC/CBD were plotted against the concentration ratios of THC/CBD for constructing the calibration curves for UHPLC-UV detection and AgPS-MS, respectively.

The accuracy and precision of the method were evaluated at three THC/CBD ratios (low (0.004), medium (0.07), and high (0.3) in sunflower oil ($n = 3$ per ratio)). The preparation of these three samples was identical to the preparation of calibration curve samples. Precision was calculated as the relative standard deviation (RSD %) ($n = 3$). Accuracy was

calculated as the relative deviation (%) of the calculated mean value from the respective reference value.

Santonin with an accurate molecular weight of 246.1256 Da was used as the internal standard for the determination of the absolute LOD and LOQ of the AgPS-MS method for THC. The characteristic MS² peaks are m/z 309 and 311 from their precursor ions, m/z 353 and 355, when analyzed by AgPS-MS. A 100.0 μL of 300.0 $\mu\text{g}\cdot\text{mL}^{-1}$ santonin in MeOH was mixed with 0.0, 1.0, 2.5, 5.0, 10.0, 25, 50, or 100 μL of a 200.0 $\mu\text{g}\cdot\text{mL}^{-1}$ THC solution in MeOH, and MeOH was added to 1.00 mL to prepare 0.0, 0.2, 0.5, 1.0, 2.0, 5.0, 10.0, or 20.0 $\mu\text{g}\cdot\text{mL}^{-1}$ THC solutions, with 30 $\mu\text{g}\cdot\text{mL}^{-1}$ santonin ($n = 3$ per concentration). The samples were analyzed by AgPS-MS under the same conditions as those used for the THC/CBD ratio analysis. The characteristic MS² fragment EIC area ratios of THC (m/z 313) to santonin (m/z 309) were plotted against the concentrations of THC for constructing a curve. LOD and LOQ were calculated as follows: LOD = $3 \times \text{SD of blank/slope of the curve}$; LOQ = $10 \times \text{SD of blank/slope of the curve}$.

Quantum Chemical Computations. Calculations of the binding energies of THC and CBD toward Ag(I) were performed with the Gaussian16 suite of programs, with the B3LYP and wB97XD functionals as implemented in there; a 6-311+G(d,p) basis set was used throughout. The electrostatic potential map was generated using Gaussview 6.

RESULTS AND DISCUSSION

THC and CBD are isomers with an accurate molecular weight of 314.2246 Da. It is difficult to distinguish between these two species by AIMS,^{31,33,34} including MS/MS analysis, as both compounds fragment into product ions with the same mass. When analyzed by PS-MS in (+) mode and setting m/z 315 as the precursor ion with an isolation width of 1.5, THC (Figure 1A) and CBD (Figure 1B) indeed yield the same MS² spectrum with the main fragments of m/z 193 and m/z 259, making differentiation impossible.

In order to effectively combine the advantages of AIMS and the potential of Ag(I) ions to bind differently to different olefinic compounds, Ag(I) was combined with PS-MS by using an Ag(I)-impregnated paper. Quasi-molecular species at m/z 421 and 423 were observed for both THC and CBD because of the existence of two silver isotopes, ¹⁰⁷Ag (52%) and ¹⁰⁹Ag (48%). By setting m/z 422 as the precursor ion and using an isolation width of 4 (thus including both m/z 421 and 423), different fragmentation patterns for THC (Figure 1C) and CBD (Figure 1D) were observed. Specifically, there was only one product ion at m/z 313 for THC, and for CBD, the most pronounced fragments appeared at m/z 353 and 355, which is the same fragment, with the mass difference because of two silver isotopes. The accurate masses and molecular formulas of the characteristic peaks for both THC and CBD Ag(I) adducts, as well as their fragments, were determined with MS/HRMS (Figure 2). After CID, [THC + Ag]⁺ loses its Ag(I) during the MS² stage, whereas the majority of [CBD + Ag]⁺ retains Ag(I) until the MS³ stage (Supporting Information, Figure S4). This finding suggests—as hypothesized—that Ag(I) binds more strongly to CBD than to THC and that this indeed leads to substantial differences in CID patterns.

This hypothesis was further substantiated by argentation HPLC–MS/MS results (Supporting Information, Figure S5). CBD [capacity factor (k') = 11.2] eluted much later than THC ($k' = 0.2$), which means that CBD has a much stronger

retention than THC on the Ag(I) column. Moreover, by quantum chemical wB97XD/6-311+G(d,p) simulations, the CBD + Ag(I) complex was found to be ~ 12 kcal/mol more stable than the THC + Ag(I) complex (Supporting Information, Figure S6), which means that a higher energy is required for the CBD + Ag(I) complex to lose its Ag(I) compared to the THC + Ag(I) complex.

Based on the above findings, a mechanism for the MS fragmentation of THC and CBD in the presence of Ag(I) was proposed. As shown in Figure 2, the [THC + Ag]⁺ adducts lose AgH during the MS² stage, but the majority of [CBD + Ag]⁺ adducts lose C₅H₈ during the MS² stage, most likely the neutral loss of 2-methyl-1,3-butadiene. The Ag(I) ion of [CBD + Ag]⁺ adducts is lost from CBD as AgCH₃ during the MS³ stage (Supporting Information, Figure S4). This difference reflects the much stronger binding of Ag(I) to CBD than to THC, which is attributed to the 1,5-diene system of CBD.^{21–23} The loss of the Ag(I) ion during the MS³ stage can be explained too because in the m/z 353/355 CBD fragment, Ag(I) complexes with a 1,3-diene system. This complexation is weaker than that with the 1,5-diene system in the quasi-molecular ion (m/z 421 and m/z 423) of CBD.²¹ In the case of the [THC + Ag]⁺ adduct, because of the oxygen–gem-dimethyl carbon bond in THC, methyl-butadiene cannot be split off, and the loss of the only weakly bound Ag(I) is to be expected. The neutral loss of either AgH or AgCH₃ is supported by the literature.^{35,36}

AgPS-MS/MS can clearly be employed to distinguish THC from CBD. However, in the MS² spectrum of CBD (Figure 1D), there is also a minor peak at m/z 313, which equals the mass of the characteristic MS² fragment of THC. This finding complicates the determination of the THC/CBD ratio. If this m/z 313 fragment would originate from a CBD-to-THC conversion, and would therefore be variable, this would preclude an accurate determination of the THC/CBD ratio. However, if it is a product ion directly originating from the fragmentation of CBD, its intensity can potentially be corrected for.

To elucidate whether the m/z 313 fragment in the CBD spectrum originated from CBD or THC, further fragmentation analysis was carried out for THC and CBD. The THC m/z 313 fragment yielded the main fragment at m/z 217 with some other minor fragments during the MS³ stage (Supporting Information, Figure S7). For CBD, the fragmentation of m/z 313 yielded a similar MS³ spectrum in which the peak at m/z 243 reproducibly had double relative intensity compared to the THC spectrum. For the fragments from m/z 313 of THC, m/z 243 and m/z 245 had equal abundance. For the fragments from m/z 313 of CBD, the abundance of m/z 243 almost doubled that of m/z 245. This suggests that the fragment of m/z 313 in the CBD MS³ spectrum is structurally different from the m/z 313 fragment in the THC MS³ spectrum.

To further exclude the possibility of conversion from CBD to THC, the peak area ratio of m/z 313/(353 + 355) was measured for pure CBD under different MS parameters ($n = 3$ per parameter), namely various source temperatures, CID energies, and CBD concentrations, as well as on two different mass spectrometers. The ratio was always constant within 2.7–3.0%, regardless of the parameter changes (Supporting Information, Figure S8), strongly suggesting that the fragment at m/z 313 in the MS² CBD spectrum is a genuine fragment of CBD, and not due to *in situ* conversion to THC, as that would have likely led to a change in the m/z 313/(353 + 355) ratio




Figure 1. PS-MS² spectrum of THC (A), PS-MS² spectrum of CBD (B), AgPS-MS² spectrum of THC (C), and AgPS-MS² spectrum of CBD (D).




Figure 2. Proposed mechanism for MS² fragmentation of THC and CBD in the presence of Ag(I).

with a change in any of these parameters. Taking all the above into consideration, we argue that the *m/z* 313 signal in the CBD AgPS-MS² spectrum is derived from CBD itself and not from THC.

When keeping all equipment parameters unchanged, the EIC area ratio of *m/z* 313 to (*m/z* 353 + *m/z* 355) in the CBD MS² spectrum is constant (0.028 ± 0.001) for a range of CBD concentrations (0.5–1000 ppm). As a result, the *m/z* 313 signal resulting from the CBD spectrum can, in the MS data from samples, be subtracted as the background value. Quantitative analysis of the THC/CBD ratio in samples can thus be achieved by measuring in the MS² spectra the EIC area ratio of *m/z* 313 to (*m/z* 353 + *m/z* 355) and then subtracting the background value of 0.028 ± 0.001 from pure CBD.

An important consideration for the cannabinoid analysis is that cannabinoids from plants are effectively in a “prodrug” form, existing as cannabinolic acids that must be decarboxylated to their respective cannabinol form to have pharmacological effects.² This decarboxylation, for example, occurs while smoking; however, upon oral consumption, no CBDA or THCA present is converted to CBD or THC by enzymatic or other processes.^{37,38} If the production and processing of CBD oils does not remove all THCA and CBDA, some THCA and CBDA might still be present in the final CBD oil products. To evaluate whether THCA and CBDA would decarboxylate to their respective cannabinol forms during the AgPS-MS analysis and would thus interfere with the quantification of the THC/CBD ratio, standard solutions of THCA and CBDA were analyzed with AgPS-MS (Supporting Information, Figure S9),

UHPLC-UV (Supporting Information, Figure S10), and HRMS (Supporting Information, Figures S11 and 12). Both THCA and CBDA formed quasi-molecular ions ($\text{Ag}(\text{I})$ adducts) at m/z 465 and 467, and no fragments at m/z 421 and 423 can be observed. Therefore, any CBDA or THCA present does not interfere with the analysis of THC and CBD when choosing m/z 421/423 as the precursor ions for fragmentation to obtain the characteristic MS^2 fragments of THC and CBD.

Recovery and Matrix Effect. To apply the findings in the practical analysis of THC and CBD in CBD oil samples, an analytical method consisting of an easy sample pretreatment step and a fast AgPS-MS procedure was developed. To determine the recovery and matrix effect, sunflower oil was selected as the matrix for THC and CBD because of the similar fatty acid composition³⁹ as hempseed oil (the main constituent of commercial CBD oil). Additionally, THC and CBD do not occur in sunflower oil.

The recovery was calculated by comparing the extract of a spiked sample to the extract of a blank matrix sample that was spiked with the same amount after extraction. In both cases, the co-extracted matrix compounds will be the same in the extract, and the only difference is caused by the recovery of the analytes. These samples were analyzed by the UHPLC-UV method, and the extraction recovery was calculated as the ratio of the average UHPLC chromatogram THC or CBD peak areas from extracted samples and nonextracted samples, and expressed as a percentage (Figure 3A). Different extraction

times have a limited effect on the recovery of both THC (86.7–90.0%) and CBD (92.3–95.6%). The slightly lower recovery of THC can be explained by the fact that THC is less polar than CBD and more likely to remain in the nonpolar sunflower oil.

The matrix effect was assessed by comparing spiked methanol with a spiked matrix extract. In both solutions, THC and CBD do not undergo any extraction step, that is, the recovery is 100%. However, pure MeOH does not contain extracted matrix compounds, whereas the blank matrix sample does. Matrix compounds might interfere with the analysis through ion suppression. The calculated ME for AgPS-MS from sunflower oil is shown in Figure 3B for various extraction times (−2.2 to −4.8 for THC and −2.0 to −3.2 for CBD). Both THC and CBD suffer the least from ion suppression when the extraction time is 1 min (−2.2 ± 0.4% for THC and −2.0 ± 0.3% for CBD), and the ion suppression becomes more pronounced when extending the extraction time (Figure 3B). However, in view of the tolerant limit for matrix effects (±25%),⁴⁰ longer extraction times would also be possible if desired.

To correct for the extraction efficiency and matrix effects in the quantification, a matrix-based calibration curve was constructed. As extraction for 1 min resulted in acceptable recoveries for THC and CBD (87.3 ± 1.2% for THC and 92.3 ± 1.4% for CBD), and minimal matrix effects (−2.2 ± 0.4% for THC, −2.0 ± 0.3% for CBD) as well as high time efficiencies, the 1 min extraction time was used in all subsequent experiments.

Calibration Curve, Precision, and Accuracy. An AgPS-MS calibration curve was constructed relating the characteristic MS^2 EIC area ratio of THC/CBD to the concentration ratio of THC/CBD in samples (Supporting Information, Figure S13A). The y -intercept of this curve is 0.0280, which means that when the sample does not contain THC, the characteristic signal ratio of THC to CBD is 0.0280, consistent with the formation of the minor fragment at m/z 313 purely by CBD. For comparison, a UHPLC-UV curve was established associating the characteristic peak area ratio of THC/CBD with the concentration ratio of THC/CBD in samples. There is good linearity ($R^2 = 0.9896$) of the AgPS-MS signal intensity over the full working range of THC/CBD ratios from 0.001 to 1 (Supporting Information, Figure S13). Even though the UHPLC-UV curve has a better linearity ($R^2 = 0.9998$), each run takes 17 min, which is much longer than that of an AgPS-MS experiment (<30 s).

Accuracy and precision of the methods were evaluated at three THC/CBD ratios of 0.004, 0.07, and 0.3 (low, medium, and high levels) in spiked sunflower oil samples and are shown in Table 1. The AgPS-MS method has comparable analytical performance as the UHPLC-UV method, with accuracy and precision for medium and high concentrations as well as acceptable accuracy and precision at low THC concentrations.




Figure 3. Recovery (A) and matrix effect (B) for THC and CBD analysis after extraction vs the extraction times. Error bars represent standard deviation ($n = 3$).

Table 1. Precision (% RSD) and Accuracy (% Deviation from True Value) of Spiked Sunflower Oil Samples

spiked THC/CBD ratio in samples	spiked absolute THC in samples ($\mu\text{g mL}^{-1}$)	spiked absolute CBD in samples ($\mu\text{g mL}^{-1}$)	UHPLC-UV result		AgPS-MS result	
			precision (%) ($N = 3$)	accuracy (%)	precision (%) ($N = 3$)	accuracy (%)
low (0.004)	0.200	50.0	2.3	8.3	11	14
medium (0.07)	3.50	50.0	2.8	4.3	7.2	−0.1
high (0.3)	15.0	50.0	1.2	1.3	1.7	−2.7

The LOD and LOQ of the AgPS-MS method to determine THC were determined at 6 and 20 ng·mL⁻¹, respectively. As the intensities in PS-MS are not very reproducible and quantification almost always relies on the use of an internal standard, santonin was used as the internal standard for THC. The [santonin + Ag]⁺ adduct (*m/z* 353 and 355) produces characteristic MS² fragments at *m/z* 309 and 311, which can be differentiated from the characteristic MS² fragment of the [THC + Ag]⁺ adduct at *m/z* 313 and thus used as the internal standard.

Application to Commercial CBD Oil Samples. Ten commercial samples were analyzed with the AgPS-MS and UHPLC-UV methods as benchmarks for their THC/CBD ratios (Figure 4A). Sunflower oil was used for the dilution of




Figure 4. THC/CBD ratio detected by AgPS-MS vs UHPLC-UV methods (A); absolute THC content based on AgPS-MS vs UHPLC-UV methods (B). Error bars represent standard deviation ($n = 3$).

CBD samples to 0.20% CBD. Because of the similar triacylglycerol composition as hemp oil, any matrix effects will be similar. The additional advantages of using sunflower oil for dilution instead of organic solvents are its availability, lack of toxicity, low cost, and environmental friendliness. Moreover, by assuming that the absolute CBD concentration as provided by the supplier is correct and taking the dilution factors into consideration, the absolute THC concentrations in these CBD oil products can be calculated. Although these do not provide direct absolute quantitative data, these estimates can serve as a screening tool to identify suspect samples that require further investigation to determine their compliance with legal standards. The clear advantage of this screening method is that it requires no addition of internal standards to the sample because of the use of the ratio between THC and CBD.

According to the results, in CBD oil_2, based on the detected ratio of THC/CBD by AgPS-MS, the calculated absolute THC concentration is $0.0226 \pm 0.0010\%$, which is almost identical with the UHPLC-UV result of $0.0236 \pm 0.0020\%$. For CBD oil_6 and CBD oil_8, AgPS-MS is unable to detect the presence of THC because of their very low THC content, which was confirmed by the UHPLC-UV analysis result. For oils with an even lower THC content, like CBD

oil_1, no THC signal was detected by either the UHPLC-UV or AgPS-MS method. Both methods revealed that CBD oils 3, 4, 5, 9, and 10 contained a relatively high THC content and are actually over the Dutch legal limit of 0.05% if the declared CBD content is correct. In other words, if the actual CBD concentration is much lower than the declared value, the calculated THC concentration may be within the legal limit, but then the CBD content on the label is incorrect. In either case, it warrants further investigation by, for example, UHPLC-UV analysis. For CBD oil_7, further analysis would be needed because the predicted result is around the legal limit, that is, $0.0571 \pm 0.0126\%$ THC based on AgPS-MS and $0.0418 \pm 0.0008\%$ based on UHPLC-UV detection.

In short, the developed method can quickly screen for the presence of THC in CBD oil by measuring the ratio of THC/CBD and determine whether the THC content is below the legal limit based on the declared CBD content. Although from the perspective of linearity, RSD, and accuracy, the UHPLC-UV methodology has a better performance, AgPS-MS greatly shortens the analysis time (from 17 min to less than 30 s). Apart from this, AgPS-MS analysis does not require any mobile phase, as only 15 μ L of MeOH is needed for spraying, making it more environmentally friendly and cheaper. Moreover, for relative quantification analysis, that is, the determination of the THC/CBD ratio, the developed method does not require the use of deuterated standards, which are difficult to obtain and are expensive.

CONCLUSIONS

Ag(I)-impregnated paper spray tandem MS allows for a fast distinction of THC and CBD, as well as for a reliable quantitative analysis of their concentration ratio. The method is based on a different complexation of THC and CBD with Ag(I) ions, leading in turn to different mass spectrometric fragmentation pathways. Samples with a wide range of THC/CBD ratios (THC/CBD = 0.001–1) can be analyzed by the developed method within tens of seconds, requiring only minimal amounts of solvent. The good correspondence between the UHPLC-UV and AgPS-MS data of commercial CBD oils confirms the applicability of the method. Thus, it could be used for quality control of CBD oils. Another application area for this screening method could be the legal control of THC-poor hemp varieties for fiber production. Positive samples can then be retested in the lab by a validated quantitative method, such as UHPLC-UV.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.analchem.0c04270>.

¹H NMR, TLC, and UHPLC analysis of THC and CBD standards; proposed CID fragmentation; argentation HPLC analysis; quantum chemical computations; influence of CID energy, temperature, and concentration on the product ion ratio; chromatographic and mass spectrometric analysis of THCA and CBDA; sample preparation and calibration curve of THC/CBD ratio constructed by AgPS-MS and UHPLC-UV; declared composition of commercial CBD oils; and AgPS-MS and UHPLC-UV analysis results of commercial CBD oils (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Han Zuilhof – Key Laboratory of Phytochemical R&D of Hunan Province and Key Laboratory of Chemical Biology & Traditional Chinese Medicine Research of Ministry of Education, Hunan Normal University, Changsha 410081, China; Laboratory of Organic Chemistry, Wageningen University, Wageningen 6708 WE, The Netherlands; Department of Chemical and Materials Engineering, Faculty of Engineering, King Abdulaziz University, Jeddah 21589, Saudi Arabia; orcid.org/0000-0001-5773-8506; Email: Han.Zuilhof@wur.nl

Gert IJ. Salentijn – Laboratory of Organic Chemistry, Wageningen University, Wageningen 6708 WE, The Netherlands; Wageningen Food Safety Research (WFSR), Wageningen University & Research, Wageningen 6700 AE, The Netherlands; orcid.org/0000-0002-2870-9084; Email: Gert.Salentijn@wur.nl

Authors

Si Huang – Key Laboratory of Phytochemical R&D of Hunan Province and Key Laboratory of Chemical Biology & Traditional Chinese Medicine Research of Ministry of Education, Hunan Normal University, Changsha 410081, China; Laboratory of Organic Chemistry, Wageningen University, Wageningen 6708 WE, The Netherlands; orcid.org/0000-0002-6792-086X

Frank W. Claassen – Laboratory of Organic Chemistry, Wageningen University, Wageningen 6708 WE, The Netherlands

Teris A. van Beek – Laboratory of Organic Chemistry, Wageningen University, Wageningen 6708 WE, The Netherlands

Bo Chen – Key Laboratory of Phytochemical R&D of Hunan Province and Key Laboratory of Chemical Biology & Traditional Chinese Medicine Research of Ministry of Education, Hunan Normal University, Changsha 410081, China; orcid.org/0000-0002-9926-4377

Jianguo Zeng – Hunan Key Laboratory of Traditional Chinese Veterinary Medicine, Hunan Agricultural University, Changsha 410128, China

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.analchem.0c04270>

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors thank Prof. Michel Nielen (Wageningen Food Safety Research) for helpful discussions and acknowledge support from the National Natural Science Foundation of China (21775040, 21775041, and 21575040), the China Scholarship Council 2020 International Cooperation Training Program for Innovative Talents, the Aid Program for S&T innovation research team in higher education institutions, the construction program of key disciplines of Hunan Province (2015JC1001), the project of Hunan Provincial Department of Education (17C0947), and the Hunan Province 100 experts project.

■ REFERENCES

- (1) Chandra, S.; Radwan, M. M.; Majumdar, C. G.; Church, J. C.; Freeman, T. P.; ElSohly, M. A. *Eur. Arch. Psychiatr. Clin. Neurosci.* **2019**, 269, 5–15.
- (2) Comeau, Z. J.; Boileau, N. T.; Lee, T.; Melville, O. A.; Rice, N. A.; Troung, Y.; Harris, C. S.; Lessard, B. H.; Shuhendler, A. J. *ACS Sens.* **2019**, 4, 2706–2715.
- (3) Pertwee, R. G. *Br. J. Pharmacol.* **2008**, 153, 199–215.
- (4) Pertwee, R. G. *Br. J. Pharmacol.* **2009**, 156, 397–411.
- (5) Marinotti, O.; Sarill, M. J. *Diet. Suppl.* **2020**, 17, 517.
- (6) Hazekamp, A. *Med. Cannabis Cannabinoids* **2018**, 1, 65–72.
- (7) Manthey, J. *Int. J. Drug Pol.* **2019**, 68, 93–96.
- (8) Borges, G. R.; Birk, L.; Scheid, C.; Morés, L.; Carasek, E.; Kitamura, R. O. S.; Roveri, F. L.; Eller, S.; de Oliveira Merib, J.; de Oliveira, T. F. *Forensic Toxicol.* **2020**, 38, 531–535.
- (9) Zivovinic, S.; Alder, R.; Allenspach, M. D.; Steuer, C. J. *Anal. Sci. Technol.* **2018**, 9, 27.
- (10) Hädener, M.; Gelmi, T. J.; Martin-Fabritius, M.; Weinmann, W.; Pfäffli, M. *Int. J. Leg. Med.* **2019**, 133, 821–832.
- (11) Amjadi, M.; Sodouri, T. J. *Appl. Spectrosc.* **2014**, 81, 232–237.
- (12) Kauppila, T. J.; Flink, A.; Laakkonen, U.-M.; Aalberg, L.; Ketola, R. A. *Drug Test. Anal.* **2013**, 5, 186–190.
- (13) Ifa, D. R.; Manicke, N. E.; Dill, A. L.; Cooks, R. G. *Science* **2008**, 321, 805.
- (14) Berman, P.; Futoran, K.; Lewitus, G. M.; Mukha, D.; Benami, M.; Shlomi, T.; Meiri, D. *Sci. Rep.* **2018**, 8, 14280.
- (15) Hädener, M.; Kamrath, M. Z.; Weinmann, W.; Groessl, M. *Anal. Chem.* **2018**, 90, 8764–8768.
- (16) Grossert, J. S.; Herrera, L. C.; Ramaley, L.; Melanson, J. E. *J. Am. Soc. Mass Spectrom.* **2014**, 25, 1421–1440.
- (17) Lévêque, N. L.; Héron, S.; Tchaplal, A. *J. Mass Spectrom.* **2010**, 45, 284–296.
- (18) Acheampong, A.; Leveque, N.; Tchaplal, A.; Heron, S. J. *Chromatogr. A* **2011**, 1218, 5087–5100.
- (19) Grade, H.; Winograd, N.; Cooks, R. G. *J. Am. Chem. Soc.* **1977**, 99, 7725–7726.
- (20) Cohen, L. H.; Gusev, A. I. *Anal. Bioanal. Chem.* **2002**, 373, 571–586.
- (21) van Beek, T. A.; Subrtova, D. *Phytochem. Anal.* **1995**, 6, 1–19.
- (22) Kaneti, J.; de Smet, L. C. P. M.; Boom, R.; Zuilhof, H.; Sudhölter, E. J. R. *J. Phys. Chem. A* **2002**, 106, 11197–11204.
- (23) Damyanova, B.; Momtchilova, S.; Bakalova, S.; Zuilhof, H.; Christie, W. W.; Kaneti, J. J. *Mol. Struct.: THEOCHEM* **2002**, 589–590, 239–249.
- (24) Feider, C. L.; Krieger, A.; DeHoog, R. J.; Eberlin, L. S. *Anal. Chem.* **2019**, 91, 4266–4290.
- (25) Jackson, A. U.; Shum, T.; Sokol, E.; Dill, A.; Cooks, R. G. *Anal. Bioanal. Chem.* **2011**, 399, 367–376.
- (26) Wang, H.; Liu, J.; Cooks, R. G.; Ouyang, Z. *Angew. Chem., Int. Ed.* **2010**, 49, 877–880.
- (27) Liu, J.; Wang, H.; Manicke, N. E.; Lin, J.-M.; Cooks, R. G.; Ouyang, Z. *Anal. Chem.* **2010**, 82, 2463–2471.
- (28) Basuri, P.; Baidya, A.; Pradeep, T. *Anal. Chem.* **2019**, 91, 7118–7124.
- (29) Bambauer, T. P.; Maurer, H. H.; Weber, A. A.; Hannig, M.; Pütz, N.; Koch, M.; Manier, S. K.; Schneider, M.; Meyer, M. R. *Talanta* **2019**, 204, 677–684.
- (30) Damon, D. E.; Davis, K. M.; Moreira, C. R.; Capone, P.; Cruttenden, R.; Badu-Tawiah, A. K. *Anal. Chem.* **2016**, 88, 1878–1884.
- (31) Duvivier, W. F.; van Beek, T. A.; Pennings, E. J. M.; Nielen, M. W. F. *Rapid Commun. Mass Spectrom.* **2014**, 28, 682–690.
- (32) Gottardo, R.; Sorio, D.; Ballotari, M.; Tagliaro, F. *J. Chromatogr. A* **2019**, 1591, 147–154.
- (33) Cody, R. B.; Laramée, J. A.; Durst, H. D. *Anal. Chem.* **2005**, 77, 2297–2302.
- (34) Duvivier, W. F.; van Putten, M. R.; van Beek, T. A.; Nielen, M. W. F. *Anal. Chem.* **2016**, 88, 2489–2496.

- (35) Shoeib, T.; Zhao, J.; Aribi, H. E.; Hopkinson, A. C.; Michael Siu, K. W. *J. Am. Soc. Mass Spectrom.* **2013**, *24*, 38–48.
- (36) Sigsworth, S. W.; Castleman, A. W. *J. Am. Chem. Soc.* **1989**, *111*, 3566–3569.
- (37) Jung, J.; Kempf, J.; Mahler, H.; Weinmann, W. *J. Mass Spectrom.* **2007**, *42*, 354–360.
- (38) Eichler, M.; Spinedi, L.; Unfer-Grauwiler, S.; Bodmer, M.; Surber, C.; Luedi, M.; Drewe, J. *Planta Med.* **2012**, *78*, 686–691.
- (39) Ariffin, A.; Bakar, J.; Tan, C.; Rahman, R.; Karim, R.; Loi, C. *Food Chem.* **2009**, *114*, 561–564.
- (40) Scientific Working Group for Forensic Toxicology. *J. Anal. Toxicol.* **2013**, *37*, 452–474.